Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.

CarlosE Vigil, Wei Tan, George Deeb, SheilaN Sait, AnnemarieW Block, Petr Starostik, ElizabethA Griffiths, JamesE Thompson, JessicaD Greene, LaurieA Ford, EuniceS Wang, Meir Wetzler

Index: Leuk. Res. 37(11) , 1468-71, (2013)

Full Text: HTML

Abstract

We designed a phase II study evaluating the upfront combination of clofarabine and daunorubicin in acute myeloid leukemia (AML) patients60 years old. The median age of the 21 patients was 69 (range 60-85) years. Fourteen patients (67%) had unfavorable risk features. The principal toxicities were grade 3 infections and prolonged myelosuppression. Three (14%) deaths occurred from infectious complications. Six (28.6%) patients achieved complete remission including three (21.4%) of 14 patients with unfavorable AML. The median disease-free survival was 6.8 months and the median overall survival was 11.2 months.